The Board of Directors has recommended 130% Cash Dividend for the year ended June 30, 2026. Date of AGM: 15.12.2026, Time: 10:00 AM, Venue: Virtual Platform. Record Date: 16.11.2026. The Company has also reported Consolidated EPS of Tk. 31.24, Consolidated NAV per share of Tk. 178.99 and Consolidated NOCFPS of Tk. 18.65 for the year ended June 30, 2026 as against Tk. 27.04, Tk. 157.88 and Tk. 19.52 respectively for the year ended June 30, 2025. The Board of Directors also approved Tk. 725.00 crore for BMRE, Capital Machineries, and Lands for future expansion.

There will be no price limit on the trading of the shares of the Company today (27.10.2026) following its corporate declaration.

As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 26, 2026 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2026.

The company has informed that the Board of Directors of the company in its meeting held on 28 June 2026 has approved agreements with M/s C2C Pharma Ltd., Dhaka, Bangladesh for contract manufacturing of some products on behalf of Square Pharmaceuticals PLC. to meet increased demand of existing products and to introduce new products. It is mentionable that DSE has requested the company to provide copy of the agreement; however, DSE is yet to receive the copy of the agreement.

(Q3 Un-audited): Consolidated EPS was Tk. 6.73 for January-March 2026 as against Tk. 6.83 for January-March 2025; Consolidated EPS was Tk. 23.29 for July 2025-March 2026 as against Tk. 21.15 for July 2024-March 2025. Consolidated NOCFPS was Tk. 17.54 for July 2025-March 2026 as against Tk. 11.90 for July 2024-March 2025. Consolidated NAV per share was Tk. 169.79 as on March 31, 2026 and Tk. 157.88 as on June 30, 2025. (Continuation news of SQURPHARMA): Reasons for Deviation in EPS and NOCFPS: Last year, revenue growth was restrained due to socio-political factors. However, in current year, not only has the business recovered from that slowdown, but it has also experienced a strong upward momentum in revenue performance consequently, both EPS and NOCFPS have recorded notable and healthy growth.

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 29, 2026 at 3:00 pm to consider, among others, Un-Audited Financial Statements for the Third Quarter (Q3) period ended March 31, 2026.

Mr. Samuel S Chowdhury, Chairman of the Company, has further informed that he has completed his buying of 2,000,000 shares of the company at prevailing market price through Dhaka Stock Exchange PLC. as per declaration disseminated on 20.01.2026.

Mrs. Ratna Patra, one of the Directors of the Company, has further informed that she has completed her buying of 1,000,000 shares of the company at prevailing market price through Dhaka Stock Exchange PLC. as per declaration disseminated on 15.01.2026.

Mr. Tapan Chowdhury, Managing Director of the company, has further informed that he has completed his buying of 2,000,000 shares of the company at prevailing market price through Dhaka Stock Exchange PLC. as per declaration disseminated on 5.01.2026.

(Q2 Un-audited): Consolidated EPS was Tk. 8.20 for October-December 2025 as against Tk. 7.45 for October-December 2024; Consolidated EPS was Tk. 16.56 for July-December 2025 as against Tk. 14.32 for July-December 2024. Consolidated NOCFPS was Tk. 13.16 for July-December 2025 as against Tk. 8.28 for July-December 2024. Consolidated NAV per share was Tk. 162.41 as on December 31, 2025 and Tk. 157.88 as on June 30, 2025. Reasons for deviations: Last year, revenue growth war restrained due to socio-political factors. However, in current year, not only has the business recovered from that slowdown, but it has also experienced a strong upward momentum in revenue performance. Consequently, both EPS and NOCFPS have recorded notable and healthy growth.